Global Compounding Chemotherapy Market By Offering (Products, Services), By Dosage (Chemotherapeutic, Non-Chemotherapeutics), By Type (Gravimetric, Volumetric), By Technology (With Robotic Arms, Without Robotic Arms), By End-Users (Hospitals and Clinics, Cancer Treatment Centers, Others), By Region (North America (U.S., Canada, Mexico, Rest of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
Compound drugs combine, mix, or change the constituents of one or more drugs to produce a new drug or product. Compound drugs may contain ingredients that have not been thoroughly evaluated for safety or efficacy. The compounded drug is created specifically for use by a covered patient to treat a covered condition. Whether the drug is harmful or not, all sterile doses should be compounded (prepared) using a stringent aseptic technique. Cancer cases in developed and developing nations are predicted to rise on an annual basis, contributing for the compounding chemotherapy market growth. Cancer is the second biggest cause of death in the United States, however many types of cancer are preventable or detectable at an early stage. According to the Centers for Disease Control and Prevention, over 1.6 million individuals in the United States are diagnosed with cancer each year, and about 600,000 die from it, making it the second leading cause of death. The growing need for personalized medication and the expansion of unmet medical needs are important drivers of compounding chemotherapy market revenue growth.
The compounding chemotherapy market is predicted to grow due to an increase in the incidence of diseases such as cancer, bone marrow diseases, and immune system problems. An increase in medical spending, as well as varying reimbursement policies, are all contributing to the market's growth. Furthermore, awareness of compounded chemotherapy treatments or medicines is another factor assisting in the compounding chemotherapy market to grow. However, high cost of compounding chemotherapeutic products (drugs) is likely to hinder the market’s growth.
Government bodies in various countries declared strict lockdowns during the COVID-19 pandemic in order to limit the spread of the disease. While this condition primarily affects the lungs, resulting in pneumonia and acute respiratory distress syndrome, it also has a negative impact on cancer treatment. The COVID-19 pandemic's impact on cancer care in the United States has resulted in decline and delays in recognizing new cancers and providing treatment in the first half of 2020. However, the increase in cases of several cancer types that require chemotherapy, such as lymphoma, lung cancer, breast cancer, myeloma, ovarian cancer, leukemia, sarcoma, and others, will ensure for the market's steady growth over the forecast period. Furthermore, the increased promise of innovation in chemotherapy drugs and treatments will provide new opportunities for the growth of compounding chemotherapy market in the healthcare sector in the near future.
In terms of revenue, global compounding chemotherapy market was valued at US$ 523.87 Mn in 2021 growing at a CAGR of 6.12% over the forecast period (2022 – 2030). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Compounding Chemotherapy Market Revenue & Forecast, (US$ Million), 2015 – 2030
Offering Outlook:
Based on offering, the global compounding chemotherapy market has been primarily segmented into products and services. The product segment accounted for a significant share of the market in 2021 owing to increased funding from the public-private organizations for research and development on cancer drugs and treatments. Moreover, market players such as COMECER S.p.A. are offering automatic compounding system "Pharmoduct", which is an automated and patented technology for the sterile manufacture of tailored oncology medications, including chemotherapy. Pharmoduct can reconstitute, move, and dilute cancer medications in order to generate patient-specific final dosages and multi-dose bags (pharmacy bulk package).
Dosage Outlook:
Based on dosage, the global compounding chemotherapy market has been segmented into chemotherapeutic, and non-chemotherapeutics. The majority of anticancer drugs have a steep dosage response relationship and a narrow therapeutic index. Proper dose selection is necessary, especially in patients with potentially curable diseases such as lymphoma or testicular cancer, and in the context of adjuvant treatment. Chemotherapeutic dosage is used to provide a variety of benefits, including preventing cancer from spreading, slowing cancer growth, and killing cancer cells that have moved to other parts of the body.
Type Outlook:
Based on type, the global compounding chemotherapy market has been segmented into gravimetric, and volumetric. The gravimetric segment is predicted to be the fastest-growing segment during the projection period, owing to the increased use of new technologies in hospitals and specialist cancer centers, as well as rising healthcare spending in both developed and developing countries. Gravimetric analysis confirms the accuracy of the additives and base solution in a product based on its measured weight by using a known specific gravity or density of each ingredient. Gravimetric is a technology capable of preventing all dosage errors while not boosting preparation accuracy.
Technology Outlook:
Based on technology, the global compounding chemotherapy market has been segmented into with robotic arms, and without robotic arms. The robotic arms segment is projected to be the fastest growing segment over the forecast period. Automated compounding devices have emerged in the market as an alternative to manual compounding of intravenous (IVD) drugs in recent years. It has several advantages, including improved uniformity of process and products, more precision of compounding, and so on.
End Users Outlook:
Based on end-users, the global compounding chemotherapy market has been segmented into hospitals and clinics, cancer treatment centers, others. The cancer treatment centers segment is projected to grow at the fastest rate in terms of CAGR in the coming years because of the increasing demand for specialist centers. Furthermore, cancer treatment centers provide world-class services in suburban outpatient centers, allowing patients to obtain treatment and consultation at a more convenient place.
Region Outlook:
Based on regions, North America recorded the highest share in the global compounding chemotherapy market in 2021, owing to increasing medical spending. The healthcare industry's key players continue to invest in diagnostics device R&D, resulting in continuous advancements in medical technology in this region.
Competitive Landscape Outlook:
The report provides both, qualitative and quantitative research of compounding chemotherapy market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings, and specification amongst others.
Some of the players operating in the compounding chemotherapy market are
- ARxIUM
- B. Braun Melsungen AG
- Baker
- Baxter
- COMECER S.p.A.
- Dedalus Italia S.p.A.
- Equashield LLC.
- Grifols International, S.A
- Icon Group
- ICU Medical
- Omnicell
- Other Market Participants
Global Compounding Chemotherapy Market:
- By Offering
- Products
- Services
- By Dosage
- Chemotherapeutic
- Non-Chemotherapeutics
- By Type
- Gravimetric
- Volumetric
- By Technology
- With Robotic Arms
- Without Robotic Arms
- By End Users
- Hospitals and Clinics
- Cancer Treatment Centers
- Others
- By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- North America
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2020
1.2.2. Base
Year: 2021
1.2.3. Forecast
Years: 2022 – 2030
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Compounding Chemotherapy Market
6. Market Synopsis:
Compounding Chemotherapy Market
7. Compounding Chemotherapy Market Analysis: Qualitative
Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Compounding Chemotherapy Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Compounding Chemotherapy Market
7.6. Porter’s
Five Force Analysis
8. Global Compounding Chemotherapy Market Analysis and
Forecasts, 2022 – 2030
8.1. Overview
8.1.1. Global
Compounding Chemotherapy Market Revenue (US$ Mn)
8.2. Global
Compounding Chemotherapy Market Revenue (US$ Mn) and Forecasts, By Offering
8.2.1. Products
8.2.1.1. Definition
8.2.1.2. Market Estimation and Penetration, 2015 - 2021
8.2.1.3. Market Forecast, 2022 – 2030
8.2.1.4. Compounding Annual Growth Rate (CAGR)
8.2.1.5. Regional Bifurcation
8.2.1.5.1. North America
8.2.1.5.1.1. Market
Estimation, 2015 - 2021
8.2.1.5.1.2. Market
Forecast, 2022 – 2030
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2015 - 2021
8.2.1.5.2.2. Market
Forecast, 2022 – 2030
8.2.1.5.3. Asia Pacific
8.2.1.5.3.1. Market
Estimation, 2015 - 2021
8.2.1.5.3.2. Market
Forecast, 2022 – 2030
8.2.1.5.4. Middle East and Africa
8.2.1.5.4.1. Market
Estimation, 2015 - 2021
8.2.1.5.4.2. Market
Forecast, 2022 – 2030
8.2.1.5.5. Latin America
8.2.1.5.5.1. Market
Estimation, 2015 - 2021
8.2.1.5.5.2. Market
Forecast, 2022 – 2030
8.2.2. Services
8.2.2.1. Definition
8.2.2.2. Market Estimation and Penetration, 2015 - 2021
8.2.2.3. Market Forecast, 2022 – 2030
8.2.2.4. Compounding Annual Growth Rate (CAGR)
8.2.2.5. Regional Bifurcation
8.2.2.5.1. North America
8.2.2.5.1.1. Market
Estimation, 2015 - 2021
8.2.2.5.1.2. Market
Forecast, 2022 – 2030
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2015 - 2021
8.2.2.5.2.2. Market
Forecast, 2022 – 2030
8.2.2.5.3. Asia Pacific
8.2.2.5.3.1. Market
Estimation, 2015 - 2021
8.2.2.5.3.2. Market
Forecast, 2022 – 2030
8.2.2.5.4. Middle East and Africa
8.2.2.5.4.1. Market
Estimation, 2015 - 2021
8.2.2.5.4.2. Market
Forecast, 2022 – 2030
8.2.2.5.5. Latin America
8.2.2.5.5.1. Market
Estimation, 2015 - 2021
8.2.2.5.5.2. Market
Forecast, 2022 – 2030
8.3. Key
Segment for Channeling Investments
8.3.1. By
Offering
9. Global Compounding Chemotherapy Market Analysis and
Forecasts, 2022 – 2030
9.1. Overview
9.2. Global
Compounding Chemotherapy Market Revenue (US$ Mn) and Forecasts, By Dosage
9.2.1. Chemotherapeutic
9.2.1.1. Definition
9.2.1.2. Market Estimation and Penetration, 2015 - 2021
9.2.1.3. Market Forecast, 2022 – 2030
9.2.1.4. Compounding Annual Growth Rate (CAGR)
9.2.1.5. Regional Bifurcation
9.2.1.5.1. North America
9.2.1.5.1.1. Market
Estimation, 2015 - 2021
9.2.1.5.1.2. Market
Forecast, 2022 – 2030
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2015 - 2021
9.2.1.5.2.2. Market
Forecast, 2022 – 2030
9.2.1.5.3. Asia Pacific
9.2.1.5.3.1. Market
Estimation, 2015 - 2021
9.2.1.5.3.2. Market
Forecast, 2022 – 2030
9.2.1.5.4. Middle East and Africa
9.2.1.5.4.1. Market
Estimation, 2015 - 2021
9.2.1.5.4.2. Market
Forecast, 2022 – 2030
9.2.1.5.5. Latin America
9.2.1.5.5.1. Market
Estimation, 2015 - 2021
9.2.1.5.5.2. Market
Forecast, 2022 – 2030
9.2.2. Non-Chemotherapeutics
9.2.2.1. Definition
9.2.2.2. Market Estimation and Penetration, 2015 - 2021
9.2.2.3. Market Forecast, 2022 – 2030
9.2.2.4. Compounding Annual Growth Rate (CAGR)
9.2.2.5. Regional Bifurcation
9.2.2.5.1. North America
9.2.2.5.1.1. Market
Estimation, 2015 - 2021
9.2.2.5.1.2. Market
Forecast, 2022 – 2030
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2015 - 2021
9.2.2.5.2.2. Market
Forecast, 2022 – 2030
9.2.2.5.3. Asia Pacific
9.2.2.5.3.1. Market
Estimation, 2015 - 2021
9.2.2.5.3.2. Market
Forecast, 2022 – 2030
9.2.2.5.4. Middle East and Africa
9.2.2.5.4.1. Market
Estimation, 2015 - 2021
9.2.2.5.4.2. Market
Forecast, 2022 – 2030
9.2.2.5.5. Latin America
9.2.2.5.5.1. Market
Estimation, 2015 - 2021
9.2.2.5.5.2. Market
Forecast, 2022 – 2030
9.3. Key
Segment for Channeling Investments
9.3.1. By
Dosage
10. Global Compounding Chemotherapy Market Analysis and
Forecasts, 2022 – 2030
10.1. Overview
10.2. Global Compounding
Chemotherapy Market Revenue (US$ Mn) and Forecasts, By Type
10.2.1. Gravimetric
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 - 2021
10.2.1.3. Market Forecast, 2022 – 2030
10.2.1.4. Compounding Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market
Estimation, 2015 - 2021
10.2.1.5.1.2. Market
Forecast, 2022 – 2030
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2015 - 2021
10.2.1.5.2.2. Market
Forecast, 2022 – 2030
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market
Estimation, 2015 - 2021
10.2.1.5.3.2. Market
Forecast, 2022 – 2030
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market
Estimation, 2015 - 2021
10.2.1.5.4.2. Market
Forecast, 2022 – 2030
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market
Estimation, 2015 - 2021
10.2.1.5.5.2. Market
Forecast, 2022 – 2030
10.2.2. Volumetric
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 - 2021
10.2.2.3. Market Forecast, 2022 – 2030
10.2.2.4. Compounding Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market
Estimation, 2015 - 2021
10.2.2.5.1.2. Market
Forecast, 2022 – 2030
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2015 - 2021
10.2.2.5.2.2. Market
Forecast, 2022 – 2030
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market
Estimation, 2015 - 2021
10.2.2.5.3.2. Market
Forecast, 2022 – 2030
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market
Estimation, 2015 - 2021
10.2.2.5.4.2. Market
Forecast, 2022 – 2030
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market
Estimation, 2015 - 2021
10.2.2.5.5.2. Market
Forecast, 2022 – 2030
10.3. Key
Segment for Channeling Investments
10.3.1. By Type
11. Global Compounding Chemotherapy Market Analysis and
Forecasts, 2022 – 2030
11.1. Overview
11.2. Global
Compounding Chemotherapy Market Revenue (US$ Mn) and Forecasts, By Technology
11.2.1. With
Robotic Arms
11.2.1.1. Definition
11.2.1.2. Market Estimation and Penetration, 2015 - 2021
11.2.1.3. Market Forecast, 2022 – 2030
11.2.1.4. Compounding Annual Growth Rate (CAGR)
11.2.1.5. Regional Bifurcation
11.2.1.5.1. North America
11.2.1.5.1.1. Market
Estimation, 2015 - 2021
11.2.1.5.1.2. Market
Forecast, 2022 – 2030
11.2.1.5.2. Europe
11.2.1.5.2.1. Market
Estimation, 2015 - 2021
11.2.1.5.2.2. Market
Forecast, 2022 – 2030
11.2.1.5.3. Asia Pacific
11.2.1.5.3.1. Market
Estimation, 2015 - 2021
11.2.1.5.3.2. Market
Forecast, 2022 – 2030
11.2.1.5.4. Middle East and Africa
11.2.1.5.4.1. Market
Estimation, 2015 - 2021
11.2.1.5.4.2. Market
Forecast, 2022 – 2030
11.2.1.5.5. Latin America
11.2.1.5.5.1. Market
Estimation, 2015 - 2021
11.2.1.5.5.2. Market
Forecast, 2022 – 2030
11.2.2. Without
Robotic Arms
11.2.2.1. Definition
11.2.2.2. Market Estimation and Penetration, 2015 - 2021
11.2.2.3. Market Forecast, 2022 – 2030
11.2.2.4. Compounding Annual Growth Rate (CAGR)
11.2.2.5. Regional Bifurcation
11.2.2.5.1. North America
11.2.2.5.1.1. Market
Estimation, 2015 - 2021
11.2.2.5.1.2. Market
Forecast, 2022 – 2030
11.2.2.5.2. Europe
11.2.2.5.2.1. Market
Estimation, 2015 - 2021
11.2.2.5.2.2. Market
Forecast, 2022 – 2030
11.2.2.5.3. Asia Pacific
11.2.2.5.3.1. Market
Estimation, 2015 - 2021
11.2.2.5.3.2. Market
Forecast, 2022 – 2030
11.2.2.5.4. Middle East and Africa
11.2.2.5.4.1. Market
Estimation, 2015 - 2021
11.2.2.5.4.2. Market
Forecast, 2022 – 2030
11.2.2.5.5. Latin America
11.2.2.5.5.1. Market
Estimation, 2015 - 2021
11.2.2.5.5.2. Market
Forecast, 2022 – 2030
11.3. Key
Segment for Channeling Investments
11.3.1. By
Technology
12. Global Compounding Chemotherapy Market Analysis and
Forecasts, 2022 – 2030
12.1. Overview
12.2. Global
Compounding Chemotherapy Market Revenue (US$ Mn) and Forecasts, By End-Users
12.2.1. Hospitals
and Clinics
12.2.1.1. Definition
12.2.1.2. Market Estimation and Penetration, 2015 - 2021
12.2.1.3. Market Forecast, 2022 – 2030
12.2.1.4. Compounding Annual Growth Rate (CAGR)
12.2.1.5. Regional Bifurcation
12.2.1.5.1. North America
12.2.1.5.1.1. Market
Estimation, 2015 - 2021
12.2.1.5.1.2. Market
Forecast, 2022 – 2030
12.2.1.5.2. Europe
12.2.1.5.2.1. Market
Estimation, 2015 - 2021
12.2.1.5.2.2. Market
Forecast, 2022 – 2030
12.2.1.5.3. Asia Pacific
12.2.1.5.3.1. Market
Estimation, 2015 - 2021
12.2.1.5.3.2. Market
Forecast, 2022 – 2030
12.2.1.5.4. Middle East and Africa
12.2.1.5.4.1. Market
Estimation, 2015 - 2021
12.2.1.5.4.2. Market
Forecast, 2022 – 2030
12.2.1.5.5. Latin America
12.2.1.5.5.1. Market
Estimation, 2015 - 2021
12.2.1.5.5.2. Market
Forecast, 2022 – 2030
12.2.2. Cancer
Treatment Centers
12.2.2.1. Definition
12.2.2.2. Market Estimation and Penetration, 2015 - 2021
12.2.2.3. Market Forecast, 2022 – 2030
12.2.2.4. Compounding Annual Growth Rate (CAGR)
12.2.2.5. Regional Bifurcation
12.2.2.5.1. North America
12.2.2.5.1.1. Market
Estimation, 2015 - 2021
12.2.2.5.1.2. Market
Forecast, 2022 – 2030
12.2.2.5.2. Europe
12.2.2.5.2.1. Market
Estimation, 2015 - 2021
12.2.2.5.2.2. Market
Forecast, 2022 – 2030
12.2.2.5.3. Asia Pacific
12.2.2.5.3.1. Market
Estimation, 2015 - 2021
12.2.2.5.3.2. Market
Forecast, 2022 – 2030
12.2.2.5.4. Middle East and Africa
12.2.2.5.4.1. Market
Estimation, 2015 - 2021
12.2.2.5.4.2. Market
Forecast, 2022 – 2030
12.2.2.5.5. Latin America
12.2.2.5.5.1. Market
Estimation, 2015 - 2021
12.2.2.5.5.2. Market
Forecast, 2022 – 2030
12.2.3. Others
12.2.3.1. Definition
12.2.3.2. Market Estimation and Penetration, 2015 - 2021
12.2.3.3. Market Forecast, 2022 – 2030
12.2.3.4. Compounding Annual Growth Rate (CAGR)
12.2.3.5. Regional Bifurcation
12.2.3.5.1. North America
12.2.3.5.1.1. Market
Estimation, 2015 - 2021
12.2.3.5.1.2. Market
Forecast, 2022 – 2030
12.2.3.5.2. Europe
12.2.3.5.2.1. Market
Estimation, 2015 - 2021
12.2.3.5.2.2. Market
Forecast, 2022 – 2030
12.2.3.5.3. Asia Pacific
12.2.3.5.3.1. Market
Estimation, 2015 - 2021
12.2.3.5.3.2. Market
Forecast, 2022 – 2030
12.2.3.5.4. Middle East and Africa
12.2.3.5.4.1. Market
Estimation, 2015 - 2021
12.2.3.5.4.2. Market
Forecast, 2022 – 2030
12.2.3.5.5. Latin America
12.2.3.5.5.1. Market
Estimation, 2015 - 2021
12.2.3.5.5.2. Market
Forecast, 2022 – 2030
12.3. Key
Segment for Channeling Investments
12.3.1. By
End-Users
13. North America Compounding Chemotherapy Market Analysis and
Forecasts, 2022 - 2030
13.1. Overview
13.1.1. North
America Compounding Chemotherapy Market Revenue (US$ Mn)
13.2. North
America Compounding Chemotherapy Market Revenue (US$ Mn) and Forecasts, By
Offering
13.2.1. Products
13.2.2. Services
13.3. North
America Compounding Chemotherapy Market Revenue (US$ Mn) and Forecasts, By
Dosage
13.3.1. Chemotherapeutic
13.3.2. Non-Chemotherapeutics
13.4. North
America Compounding Chemotherapy Market Revenue (US$ Mn) and Forecasts, By Type
13.4.1. Gravimetric
13.4.2. Volumetric
13.5. North
America Compounding Chemotherapy Market Revenue (US$ Mn) and Forecasts, By
Technology
13.5.1. With
Robotic Arms
13.5.2. Without
Robotic Arms
13.6. North
America Compounding Chemotherapy Market Revenue (US$ Mn) and Forecasts, By
End-Users
13.6.1. Hospitals
and Clinics
13.6.2. Cancer
Treatment Centers
13.6.3. Others
13.7. North
America Compounding Chemotherapy Market Revenue (US$ Mn) and Forecasts, By
Country
13.7.1. U.S
13.7.1.1. U.S Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Offering
13.7.1.1.1. Products
13.7.1.1.2. Services
13.7.1.2. U.S Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Dosage
13.7.1.2.1. Chemotherapeutic
13.7.1.2.2. Non-Chemotherapeutics
13.7.1.3. U.S Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Type
13.7.1.3.1. Gravimetric
13.7.1.3.2. Volumetric
13.7.1.4. U.S Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Technology
13.7.1.4.1. With Robotic Arms
13.7.1.4.2. Without Robotic Arms
13.7.1.5. U.S Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By End-Users
13.7.1.5.1. Hospitals and Clinics
13.7.1.5.2. Cancer Treatment Centers
13.7.1.5.3. Others
13.7.2. Canada
13.7.2.1. Canada Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Offering
13.7.2.1.1. Products
13.7.2.1.2. Services
13.7.2.2. Canada Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Dosage
13.7.2.2.1. Chemotherapeutic
13.7.2.2.2. Non-Chemotherapeutics
13.7.2.3. Canada Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Type
13.7.2.3.1. Gravimetric
13.7.2.3.2. Volumetric
13.7.2.4. Canada Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Technology
13.7.2.4.1. With Robotic Arms
13.7.2.4.2. Without Robotic Arms
13.7.2.5. Canada Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By End-Users
13.7.2.5.1. Hospitals and Clinics
13.7.2.5.2. Cancer Treatment Centers
13.7.2.5.3. Others
13.7.3. Mexico
13.7.3.1. Mexico Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Offering
13.7.3.1.1. Products
13.7.3.1.2. Services
13.7.3.2. Mexico Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Dosage
13.7.3.2.1. Chemotherapeutic
13.7.3.2.2. Non-Chemotherapeutics
13.7.3.3. Mexico Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Type
13.7.3.3.1. Gravimetric
13.7.3.3.2. Volumetric
13.7.3.4. Mexico Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Technology
13.7.3.4.1. With Robotic Arms
13.7.3.4.2. Without Robotic Arms
13.7.3.5. Mexico Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By End-Users
13.7.3.5.1. Hospitals and Clinics
13.7.3.5.2. Cancer Treatment Centers
13.7.3.5.3. Others
13.7.4. Rest of
North America
13.7.4.1. Rest of North America Compounding Chemotherapy Market Revenue
(US$ Mn) and Forecasts, By Offering
13.7.4.1.1. Products
13.7.4.1.2. Services
13.7.4.2. Rest of North America Compounding Chemotherapy Market Revenue
(US$ Mn) and Forecasts, By Dosage
13.7.4.2.1. Chemotherapeutic
13.7.4.2.2. Non-Chemotherapeutics
13.7.4.3. Rest of North America Compounding Chemotherapy Market Revenue
(US$ Mn) and Forecasts, By Type
13.7.4.3.1. Gravimetric
13.7.4.3.2. Volumetric
13.7.4.4. Rest of North America Compounding Chemotherapy Market Revenue
(US$ Mn) and Forecasts, By Technology
13.7.4.4.1. With Robotic Arms
13.7.4.4.2. Without Robotic Arms
13.7.4.5. Rest of North America Compounding Chemotherapy Market Revenue
(US$ Mn) and Forecasts, By End-Users
13.7.4.5.1. Hospitals and Clinics
13.7.4.5.2. Cancer Treatment Centers
13.7.4.5.3. Others
13.8. Key
Segment for Channeling Investments
13.8.1. By
Country
13.8.2. By
Offering
13.8.3. By Dosage
13.8.4. By Type
13.8.5. By
Technology
13.8.6. By
End-Users
14. Europe Compounding Chemotherapy Market Analysis and
Forecasts, 2022 - 2030
14.1. Overview
14.1.1. Europe
Compounding Chemotherapy Market Revenue (US$ Mn)
14.2. Europe
Compounding Chemotherapy Market Revenue (US$ Mn) and Forecasts, By Offering
14.2.1. Products
14.2.2. Services
14.3. Europe
Compounding Chemotherapy Market Revenue (US$ Mn) and Forecasts, By Dosage
14.3.1. Chemotherapeutic
14.3.2. Non-Chemotherapeutics
14.4. Europe
Compounding Chemotherapy Market Revenue (US$ Mn) and Forecasts, By Type
14.4.1. Gravimetric
14.4.2. Volumetric
14.5. Europe Compounding
Chemotherapy Market Revenue (US$ Mn) and Forecasts, By Technology
14.5.1. With
Robotic Arms
14.5.2. Without
Robotic Arms
14.6. Europe
Compounding Chemotherapy Market Revenue (US$ Mn) and Forecasts, By End-Users
14.6.1. Hospitals
and Clinics
14.6.2. Cancer
Treatment Centers
14.6.3. Others
14.7. Europe
Compounding Chemotherapy Market Revenue (US$ Mn) and Forecasts, By Country
14.7.1. France
14.7.1.1. France Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Offering
14.7.1.1.1. Products
14.7.1.1.2. Services
14.7.1.2. France Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Dosage
14.7.1.2.1. Chemotherapeutic
14.7.1.2.2. Non-Chemotherapeutics
14.7.1.3. France Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Type
14.7.1.3.1. Gravimetric
14.7.1.3.2. Volumetric
14.7.1.4. France Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Technology
14.7.1.4.1. With Robotic Arms
14.7.1.4.2. Without Robotic Arms
14.7.1.5. France Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By End-Users
14.7.1.5.1. Hospitals and Clinics
14.7.1.5.2. Cancer Treatment Centers
14.7.1.5.3. Others
14.7.2. The UK
14.7.2.1. The UK Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Offering
14.7.2.1.1. Products
14.7.2.1.2. Services
14.7.2.2. The UK Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Dosage
14.7.2.2.1. Chemotherapeutic
14.7.2.2.2. Non-Chemotherapeutics
14.7.2.3. The UK Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Type
14.7.2.3.1. Gravimetric
14.7.2.3.2. Volumetric
14.7.2.4. The UK Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Technology
14.7.2.4.1. With Robotic Arms
14.7.2.4.2. Without Robotic Arms
14.7.2.5. The UK Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By End-Users
14.7.2.5.1. Hospitals and Clinics
14.7.2.5.2. Cancer Treatment Centers
14.7.2.5.3. Others
14.7.3. Spain
14.7.3.1. Spain Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Offering
14.7.3.1.1. Products
14.7.3.1.2. Services
14.7.3.2. Spain Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Dosage
14.7.3.2.1. Chemotherapeutic
14.7.3.2.2. Non-Chemotherapeutics
14.7.3.3. Spain Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Type
14.7.3.3.1. Gravimetric
14.7.3.3.2. Volumetric
14.7.3.4. Spain Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Technology
14.7.3.4.1. With Robotic Arms
14.7.3.4.2. Without Robotic Arms
14.7.3.5. Spain Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By End-Users
14.7.3.5.1. Hospitals and Clinics
14.7.3.5.2. Cancer Treatment Centers
14.7.3.5.3. Others
14.7.4. Germany
14.7.4.1. Germany Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Offering
14.7.4.1.1. Products
14.7.4.1.2. Services
14.7.4.2. Germany Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Dosage
14.7.4.2.1. Chemotherapeutic
14.7.4.2.2. Non-Chemotherapeutics
14.7.4.3. Germany Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Type
14.7.4.3.1. Gravimetric
14.7.4.3.2. Volumetric
14.7.4.4. Germany Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Technology
14.7.4.4.1. With Robotic Arms
14.7.4.4.2. Without Robotic Arms
14.7.4.5. Germany Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By End-Users
14.7.4.5.1. Hospitals and Clinics
14.7.4.5.2. Cancer Treatment Centers
14.7.4.5.3. Others
14.7.5. Italy
14.7.5.1. Italy Compounding Chemotherapy Market Revenue (US$ Mn) and Forecasts,
By Offering
14.7.5.1.1. Products
14.7.5.1.2. Services
14.7.5.2. Italy Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Dosage
14.7.5.2.1. Chemotherapeutic
14.7.5.2.2. Non-Chemotherapeutics
14.7.5.3. Italy Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Type
14.7.5.3.1. Gravimetric
14.7.5.3.2. Volumetric
14.7.5.4. Italy Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Technology
14.7.5.4.1. With Robotic Arms
14.7.5.4.2. Without Robotic Arms
14.7.5.5. Italy Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By End-Users
14.7.5.5.1. Hospitals and Clinics
14.7.5.5.2. Cancer Treatment Centers
14.7.5.5.3. Others
14.7.6. Nordic
Countries
14.7.6.1. Nordic Countries Compounding Chemotherapy Market Revenue (US$
Mn) and Forecasts, By Offering
14.7.6.1.1. Products
14.7.6.1.2. Services
14.7.6.2. Nordic Countries Compounding Chemotherapy Market Revenue (US$
Mn) and Forecasts, By Dosage
14.7.6.2.1. Chemotherapeutic
14.7.6.2.2. Non-Chemotherapeutics
14.7.6.3. Nordic Countries Compounding Chemotherapy Market Revenue (US$
Mn) and Forecasts, By Type
14.7.6.3.1. Gravimetric
14.7.6.3.2. Volumetric
14.7.6.4. Nordic Countries Compounding Chemotherapy Market Revenue (US$
Mn) and Forecasts, By Technology
14.7.6.4.1. With Robotic Arms
14.7.6.4.2. Without Robotic Arms
14.7.6.5. Nordic Countries Compounding Chemotherapy Market Revenue (US$
Mn) and Forecasts, By End-Users
14.7.6.5.1. Hospitals and Clinics
14.7.6.5.2. Cancer Treatment Centers
14.7.6.5.3. Others
14.7.6.6. Nordic Countries Compounding Chemotherapy Market Revenue (US$
Mn) and Forecasts, By Country
14.7.6.6.1. Denmark
14.7.6.6.2. Finland
14.7.6.6.3. Iceland
14.7.6.6.4. Sweden
14.7.6.6.5. Norway
14.7.7. Benelux
Union
14.7.7.1. Benelux Union Compounding Chemotherapy Market Revenue (US$ Mn)
and Forecasts, By Offering
14.7.7.1.1. Products
14.7.7.1.2. Services
14.7.7.2. Benelux Union Compounding Chemotherapy Market Revenue (US$ Mn)
and Forecasts, By Dosage
14.7.7.2.1. Chemotherapeutic
14.7.7.2.2. Non-Chemotherapeutics
14.7.7.3. Benelux Union Compounding Chemotherapy Market Revenue (US$ Mn)
and Forecasts, By Type
14.7.7.3.1. Gravimetric
14.7.7.3.2. Volumetric
14.7.7.4. Benelux Union Compounding Chemotherapy Market Revenue (US$ Mn)
and Forecasts, By Technology
14.7.7.4.1. With Robotic Arms
14.7.7.4.2. Without Robotic Arms
14.7.7.5. Benelux Union Compounding Chemotherapy Market Revenue (US$ Mn)
and Forecasts, By End-Users
14.7.7.5.1. Hospitals and Clinics
14.7.7.5.2. Cancer Treatment Centers
14.7.7.5.3. Others
14.7.7.6. Benelux Union Compounding Chemotherapy Market Revenue (US$ Mn)
and Forecasts, By Country
14.7.7.6.1. Belgium
14.7.7.6.2. The Netherlands
14.7.7.6.3. Luxembourg
14.7.8. Rest of
Europe
14.7.8.1. Rest of Europe Compounding Chemotherapy Market Revenue (US$
Mn) and Forecasts, By Offering
14.7.8.1.1. Products
14.7.8.1.2. Services
14.7.8.2. Rest of Europe Compounding Chemotherapy Market Revenue (US$
Mn) and Forecasts, By Dosage
14.7.8.2.1. Chemotherapeutic
14.7.8.2.2. Non-Chemotherapeutics
14.7.8.3. Rest of Europe Compounding Chemotherapy Market Revenue (US$
Mn) and Forecasts, By Type
14.7.8.3.1. Gravimetric
14.7.8.3.2. Volumetric
14.7.8.4. Rest of Europe Compounding Chemotherapy Market Revenue (US$
Mn) and Forecasts, By Technology
14.7.8.4.1. With Robotic Arms
14.7.8.4.2. Without Robotic Arms
14.7.8.5. Rest of Europe Compounding Chemotherapy Market Revenue (US$
Mn) and Forecasts, By End-Users
14.7.8.5.1. Hospitals and Clinics
14.7.8.5.2. Cancer Treatment Centers
14.7.8.5.3. Others
14.8. Key
Segment for Channeling Investments
14.8.1. By
Country
14.8.2. By
Offering
14.8.3. By Dosage
14.8.4. By Type
14.8.5. By
Technology
14.8.6. By
End-Users
15. Asia Pacific Compounding Chemotherapy Market Analysis and
Forecasts, 2022 - 2030
15.1. Overview
15.1.1. Asia
Pacific Compounding Chemotherapy Market Revenue (US$ Mn)
15.2. Asia
Pacific Compounding Chemotherapy Market Revenue (US$ Mn) and Forecasts, By
Offering
15.2.1. Products
15.2.2. Services
15.3. Asia
Pacific Compounding Chemotherapy Market Revenue (US$ Mn) and Forecasts, By
Dosage
15.3.1. Chemotherapeutic
15.3.2. Non-Chemotherapeutics
15.4. Asia
Pacific Compounding Chemotherapy Market Revenue (US$ Mn) and Forecasts, By Type
15.4.1. Gravimetric
15.4.2. Volumetric
15.5. Asia
Pacific Compounding Chemotherapy Market Revenue (US$ Mn) and Forecasts, By
Technology
15.5.1. With
Robotic Arms
15.5.2. Without
Robotic Arms
15.6. Asia
Pacific Compounding Chemotherapy Market Revenue (US$ Mn) and Forecasts, By
End-Users
15.6.1. Hospitals
and Clinics
15.6.2. Cancer
Treatment Centers
15.6.3. Others
15.7. Asia
Pacific Compounding Chemotherapy Market Revenue (US$ Mn) and Forecasts, By
Country
15.7.1. China
15.7.1.1. China Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Offering
15.7.1.1.1. Products
15.7.1.1.2. Services
15.7.1.2. China Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Dosage
15.7.1.2.1. Chemotherapeutic
15.7.1.2.2. Non-Chemotherapeutics
15.7.1.3. China Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Type
15.7.1.3.1. Gravimetric
15.7.1.3.2. Volumetric
15.7.1.4. China Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Technology
15.7.1.4.1. With Robotic Arms
15.7.1.4.2. Without Robotic Arms
15.7.1.5. China Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By End-Users
15.7.1.5.1. Hospitals and Clinics
15.7.1.5.2. Cancer Treatment Centers
15.7.1.5.3. Others
15.7.2. Japan
15.7.2.1. Japan Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Offering
15.7.2.1.1. Products
15.7.2.1.2. Services
15.7.2.2. Japan Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Dosage
15.7.2.2.1. Chemotherapeutic
15.7.2.2.2. Non-Chemotherapeutics
15.7.2.3. Japan Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Type
15.7.2.3.1. Gravimetric
15.7.2.3.2. Volumetric
15.7.2.4. Japan Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Technology
15.7.2.4.1. With Robotic Arms
15.7.2.4.2. Without Robotic Arms
15.7.2.5. Japan Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By End-Users
15.7.2.5.1. Hospitals and Clinics
15.7.2.5.2. Cancer Treatment Centers
15.7.2.5.3. Others
15.7.3. India
15.7.3.1. India Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Offering
15.7.3.1.1. Products
15.7.3.1.2. Services
15.7.3.2. India Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Dosage
15.7.3.2.1. Chemotherapeutic
15.7.3.2.2. Non-Chemotherapeutics
15.7.3.3. India Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Type
15.7.3.3.1. Gravimetric
15.7.3.3.2. Volumetric
15.7.3.4. India Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Technology
15.7.3.4.1. With Robotic Arms
15.7.3.4.2. Without Robotic Arms
15.7.3.5. India Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By End-Users
15.7.3.5.1. Hospitals and Clinics
15.7.3.5.2. Cancer Treatment Centers
15.7.3.5.3. Others
15.7.4. New
Zealand
15.7.4.1. New Zealand Compounding Chemotherapy Market Revenue (US$ Mn)
and Forecasts, By Offering
15.7.4.1.1. Products
15.7.4.1.2. Services
15.7.4.2. New Zealand Compounding Chemotherapy Market Revenue (US$ Mn)
and Forecasts, By Dosage
15.7.4.2.1. Chemotherapeutic
15.7.4.2.2. Non-Chemotherapeutics
15.7.4.3. New Zealand Compounding Chemotherapy Market Revenue (US$ Mn)
and Forecasts, By Type
15.7.4.3.1. Gravimetric
15.7.4.3.2. Volumetric
15.7.4.4. New Zealand Compounding Chemotherapy Market Revenue (US$ Mn)
and Forecasts, By Technology
15.7.4.4.1. With Robotic Arms
15.7.4.4.2. Without Robotic Arms
15.7.4.5. New Zealand Compounding Chemotherapy Market Revenue (US$ Mn)
and Forecasts, By End-Users
15.7.4.5.1. Hospitals and Clinics
15.7.4.5.2. Cancer Treatment Centers
15.7.4.5.3. Others
15.7.5. Australia
15.7.5.1. Australia Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Offering
15.7.5.1.1. Products
15.7.5.1.2. Services
15.7.5.2. Australia Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Dosage
15.7.5.2.1. Chemotherapeutic
15.7.5.2.2. Non-Chemotherapeutics
15.7.5.3. Australia Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Type
15.7.5.3.1. Gravimetric
15.7.5.3.2. Volumetric
15.7.5.4. Australia Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Technology
15.7.5.4.1. With Robotic Arms
15.7.5.4.2. Without Robotic Arms
15.7.5.5. Australia Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By End-Users
15.7.5.5.1. Hospitals and Clinics
15.7.5.5.2. Cancer Treatment Centers
15.7.5.5.3. Others
15.7.6. South
Korea
15.7.6.1. South Korea Compounding Chemotherapy Market Revenue (US$ Mn)
and Forecasts, By Offering
15.7.6.1.1. Products
15.7.6.1.2. Services
15.7.6.2. South Korea Compounding Chemotherapy Market Revenue (US$ Mn)
and Forecasts, By Dosage
15.7.6.2.1. Chemotherapeutic
15.7.6.2.2. Non-Chemotherapeutics
15.7.6.3. South Korea Compounding Chemotherapy Market Revenue (US$ Mn)
and Forecasts, By Type
15.7.6.3.1. Gravimetric
15.7.6.3.2. Volumetric
15.7.6.4. South Korea Compounding Chemotherapy Market Revenue (US$ Mn)
and Forecasts, By Technology
15.7.6.4.1. With Robotic Arms
15.7.6.4.2. Without Robotic Arms
15.7.6.5. South Korea Compounding Chemotherapy Market Revenue (US$ Mn)
and Forecasts, By End-Users
15.7.6.5.1. Hospitals and Clinics
15.7.6.5.2. Cancer Treatment Centers
15.7.6.5.3. Others
15.7.7. Southeast
Asia
15.7.7.1. Southeast Asia Compounding Chemotherapy Market Revenue (US$
Mn) and Forecasts, By Offering
15.7.7.1.1. Products
15.7.7.1.2. Services
15.7.7.2. Southeast Asia Compounding Chemotherapy Market Revenue (US$
Mn) and Forecasts, By Dosage
15.7.7.2.1. Chemotherapeutic
15.7.7.2.2. Non-Chemotherapeutics
15.7.7.3. Southeast Asia Compounding Chemotherapy Market Revenue (US$
Mn) and Forecasts, By Type
15.7.7.3.1. Gravimetric
15.7.7.3.2. Volumetric
15.7.7.4. Southeast Asia Compounding Chemotherapy Market Revenue (US$
Mn) and Forecasts, By Technology
15.7.7.4.1. With Robotic Arms
15.7.7.4.2. Without Robotic Arms
15.7.7.5. Southeast Asia Compounding Chemotherapy Market Revenue (US$
Mn) and Forecasts, By End-Users
15.7.7.5.1. Hospitals and Clinics
15.7.7.5.2. Cancer Treatment Centers
15.7.7.5.3. Others
15.7.7.6. Southeast Asia Compounding Chemotherapy Market Revenue (US$
Mn) and Forecasts, By Country
15.7.7.6.1. Indonesia
15.7.7.6.2. Thailand
15.7.7.6.3. Malaysia
15.7.7.6.4. Singapore
15.7.7.6.5. Rest of Southeast Asia
15.7.8. Rest of
Asia Pacific
15.7.8.1. Rest of Asia Pacific Compounding Chemotherapy Market Revenue
(US$ Mn) and Forecasts, By Offering
15.7.8.1.1. Products
15.7.8.1.2. Services
15.7.8.2. Rest of Asia Pacific Compounding Chemotherapy Market Revenue
(US$ Mn) and Forecasts, By Dosage
15.7.8.2.1. Chemotherapeutic
15.7.8.2.2. Non-Chemotherapeutics
15.7.8.3. Rest of Asia Pacific Compounding Chemotherapy Market Revenue
(US$ Mn) and Forecasts, By Type
15.7.8.3.1. Gravimetric
15.7.8.3.2. Volumetric
15.7.8.4. Rest of Asia Pacific Compounding Chemotherapy Market Revenue
(US$ Mn) and Forecasts, By Technology
15.7.8.4.1. With Robotic Arms
15.7.8.4.2. Without Robotic Arms
15.7.8.5. Rest of Asia Pacific Compounding Chemotherapy Market Revenue
(US$ Mn) and Forecasts, By End-Users
15.7.8.5.1. Hospitals and Clinics
15.7.8.5.2. Cancer Treatment Centers
15.7.8.5.3. Others
15.8. Key
Segment for Channeling Investments
15.8.1. By
Country
15.8.2. By
Offering
15.8.3. By
Dosage
15.8.4. By Type
15.8.5. By
Technology
15.8.6. By
End-Users
16. Middle East and Africa Compounding Chemotherapy Market
Analysis and Forecasts, 2022 - 2030
16.1. Overview
16.1.1. Middle
East and Africa Compounding Chemotherapy Market Revenue (US$ Mn)
16.2. Middle
East and Africa Compounding Chemotherapy Market Revenue (US$ Mn) and Forecasts,
By Offering
16.2.1. Products
16.2.2. Services
16.3. Middle
East and Africa Compounding Chemotherapy Market Revenue (US$ Mn) and Forecasts,
By Dosage
16.3.1. Chemotherapeutic
16.3.2. Non-Chemotherapeutics
16.4. Middle
East and Africa Compounding Chemotherapy Market Revenue (US$ Mn) and Forecasts,
By Type
16.4.1. Gravimetric
16.4.2. Volumetric
16.5. Middle
East and Africa Compounding Chemotherapy Market Revenue (US$ Mn) and Forecasts,
By Technology
16.5.1. With
Robotic Arms
16.5.2. Without
Robotic Arms
16.6. Middle
East and Africa Compounding Chemotherapy Market Revenue (US$ Mn) and Forecasts,
By End-Users
16.6.1. Hospitals
and Clinics
16.6.2. Cancer
Treatment Centers
16.6.3. Others
16.7. Middle
East and Africa Compounding Chemotherapy Market Revenue (US$ Mn) and Forecasts,
By Country
16.7.1. Saudi
Arabia
16.7.1.1. Saudi Arabia Compounding Chemotherapy Market Revenue (US$ Mn)
and Forecasts, By Offering
16.7.1.1.1. Products
16.7.1.1.2. Services
16.7.1.2. Saudi Arabia Compounding Chemotherapy Market Revenue (US$ Mn)
and Forecasts, By Dosage
16.7.1.2.1. Chemotherapeutic
16.7.1.2.2. Non-Chemotherapeutics
16.7.1.3. Saudi Arabia Compounding Chemotherapy Market Revenue (US$ Mn)
and Forecasts, By Type
16.7.1.3.1. Gravimetric
16.7.1.3.2. Volumetric
16.7.1.4. Saudi Arabia Compounding Chemotherapy Market Revenue (US$ Mn)
and Forecasts, By Technology
16.7.1.4.1. With Robotic Arms
16.7.1.4.2. Without Robotic Arms
16.7.1.5. Saudi Arabia Compounding Chemotherapy Market Revenue (US$ Mn)
and Forecasts, By End-Users
16.7.1.5.1. Hospitals and Clinics
16.7.1.5.2. Cancer Treatment Centers
16.7.1.5.3. Others
16.7.2. UAE
16.7.2.1. UAE Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Offering
16.7.2.1.1. Products
16.7.2.1.2. Services
16.7.2.2. UAE Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Dosage
16.7.2.2.1. Chemotherapeutic
16.7.2.2.2. Non-Chemotherapeutics
16.7.2.3. UAE Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Type
16.7.2.3.1. Gravimetric
16.7.2.3.2. Volumetric
16.7.2.4. UAE Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Technology
16.7.2.4.1. With Robotic Arms
16.7.2.4.2. Without Robotic Arms
16.7.2.5. UAE Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By End-Users
16.7.2.5.1. Hospitals and Clinics
16.7.2.5.2. Cancer Treatment Centers
16.7.2.5.3. Others
16.7.3. Egypt
16.7.3.1. Egypt Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Offering
16.7.3.1.1. Products
16.7.3.1.2. Services
16.7.3.2. Egypt Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Dosage
16.7.3.2.1. Chemotherapeutic
16.7.3.2.2. Non-Chemotherapeutics
16.7.3.3. Egypt Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Type
16.7.3.3.1. Gravimetric
16.7.3.3.2. Volumetric
16.7.3.4. Egypt Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Technology
16.7.3.4.1. With Robotic Arms
16.7.3.4.2. Without Robotic Arms
16.7.3.5. Egypt Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By End-Users
16.7.3.5.1. Hospitals and Clinics
16.7.3.5.2. Cancer Treatment Centers
16.7.3.5.3. Others
16.7.4. Kuwait
16.7.4.1. Kuwait Compounding Chemotherapy Market Revenue (US$ Mn) and Forecasts,
By Offering
16.7.4.1.1. Products
16.7.4.1.2. Services
16.7.4.2. Kuwait Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Dosage
16.7.4.2.1. Chemotherapeutic
16.7.4.2.2. Non-Chemotherapeutics
16.7.4.3. Kuwait Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Type
16.7.4.3.1. Gravimetric
16.7.4.3.2. Volumetric
16.7.4.4. Kuwait Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Technology
16.7.4.4.1. With Robotic Arms
16.7.4.4.2. Without Robotic Arms
16.7.4.5. Kuwait Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By End-Users
16.7.4.5.1. Hospitals and Clinics
16.7.4.5.2. Cancer Treatment Centers
16.7.4.5.3. Others
16.7.5. South
Africa
16.7.5.1. South Africa Compounding Chemotherapy Market Revenue (US$ Mn)
and Forecasts, By Offering
16.7.5.1.1. Products
16.7.5.1.2. Services
16.7.5.2. South Africa Compounding Chemotherapy Market Revenue (US$ Mn)
and Forecasts, By Dosage
16.7.5.2.1. Chemotherapeutic
16.7.5.2.2. Non-Chemotherapeutics
16.7.5.3. South Africa Compounding Chemotherapy Market Revenue (US$ Mn)
and Forecasts, By Type
16.7.5.3.1. Gravimetric
16.7.5.3.2. Volumetric
16.7.5.4. South Africa Compounding Chemotherapy Market Revenue (US$ Mn)
and Forecasts, By Technology
16.7.5.4.1. With Robotic Arms
16.7.5.4.2. Without Robotic Arms
16.7.5.5. South Africa Compounding Chemotherapy Market Revenue (US$ Mn)
and Forecasts, By End-Users
16.7.5.5.1. Hospitals and Clinics
16.7.5.5.2. Cancer Treatment Centers
16.7.5.5.3. Others
16.7.6. Rest of
Middle East & Africa
16.7.6.1. Rest of Middle East & Africa Compounding Chemotherapy
Market Revenue (US$ Mn) and Forecasts, By Offering
16.7.6.1.1. Products
16.7.6.1.2. Services
16.7.6.2. Rest of Middle East & Africa Compounding Chemotherapy
Market Revenue (US$ Mn) and Forecasts, By Dosage
16.7.6.2.1. Chemotherapeutic
16.7.6.2.2. Non-Chemotherapeutics
16.7.6.3. Rest of Middle East & Africa Compounding Chemotherapy
Market Revenue (US$ Mn) and Forecasts, By Type
16.7.6.3.1. Gravimetric
16.7.6.3.2. Volumetric
16.7.6.4. Rest of Middle East & Africa Compounding Chemotherapy
Market Revenue (US$ Mn) and Forecasts, By Technology
16.7.6.4.1. With Robotic Arms
16.7.6.4.2. Without Robotic Arms
16.7.6.5. Rest of Middle East & Africa Compounding Chemotherapy
Market Revenue (US$ Mn) and Forecasts, By End-Users
16.7.6.5.1. Hospitals and Clinics
16.7.6.5.2. Cancer Treatment Centers
16.7.6.5.3. Others
16.8. Key
Segment for Channeling Investments
16.8.1. By
Country
16.8.2. By
Offering
16.8.3. By
Dosage
16.8.4. By Type
16.8.5. By
Technology
16.8.6. By
End-Users
17. Latin America Compounding Chemotherapy Market Analysis and
Forecasts, 2022 - 2030
17.1. Overview
17.1.1. Latin
America Compounding Chemotherapy Market Revenue (US$ Mn)
17.2. Latin
America Compounding Chemotherapy Market Revenue (US$ Mn) and Forecasts, By
Offering
17.2.1. Products
17.2.2. Services
17.3. Latin
America Compounding Chemotherapy Market Revenue (US$ Mn) and Forecasts, By
Dosage
17.3.1. Chemotherapeutic
17.3.2. Non-Chemotherapeutics
17.4. Latin
America Compounding Chemotherapy Market Revenue (US$ Mn) and Forecasts, By Type
17.4.1. Gravimetric
17.4.2. Volumetric
17.5. Latin America
Compounding Chemotherapy Market Revenue (US$ Mn) and Forecasts, By Technology
17.5.1. With
Robotic Arms
17.5.2. Without
Robotic Arms
17.6. Latin
America Compounding Chemotherapy Market Revenue (US$ Mn) and Forecasts, By
End-Users
17.6.1. Hospitals
and Clinics
17.6.2. Cancer
Treatment Centers
17.6.3. Others
17.7. Latin
America Compounding Chemotherapy Market Revenue (US$ Mn) and Forecasts, By
Country
17.7.1. Brazil
17.7.1.1. Brazil Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Offering
17.7.1.1.1. Products
17.7.1.1.2. Services
17.7.1.2. Brazil Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Dosage
17.7.1.2.1. Chemotherapeutic
17.7.1.2.2. Non-Chemotherapeutics
17.7.1.3. Brazil Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Type
17.7.1.3.1. Gravimetric
17.7.1.3.2. Volumetric
17.7.1.4. Brazil Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Technology
17.7.1.4.1. With Robotic Arms
17.7.1.4.2. Without Robotic Arms
17.7.1.5. Brazil Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By End-Users
17.7.1.5.1. Hospitals and Clinics
17.7.1.5.2. Cancer Treatment Centers
17.7.1.5.3. Others
17.7.2. Argentina
17.7.2.1. Argentina Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Offering
17.7.2.1.1. Products
17.7.2.1.2. Services
17.7.2.2. Argentina Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Dosage
17.7.2.2.1. Chemotherapeutic
17.7.2.2.2. Non-Chemotherapeutics
17.7.2.3. Argentina Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Type
17.7.2.3.1. Gravimetric
17.7.2.3.2. Volumetric
17.7.2.4. Argentina Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By Technology
17.7.2.4.1. With Robotic Arms
17.7.2.4.2. Without Robotic Arms
17.7.2.5. Argentina Compounding Chemotherapy Market Revenue (US$ Mn) and
Forecasts, By End-Users
17.7.2.5.1. Hospitals and Clinics
17.7.2.5.2. Cancer Treatment Centers
17.7.2.5.3. Others
17.7.3. Rest of
Latin America
17.7.3.1. Rest of Latin America Compounding Chemotherapy Market Revenue
(US$ Mn) and Forecasts, By Offering
17.7.3.1.1. Products
17.7.3.1.2. Services
17.7.3.2. Rest of Latin America Compounding Chemotherapy Market Revenue
(US$ Mn) and Forecasts, By Dosage
17.7.3.2.1. Chemotherapeutic
17.7.3.2.2. Non-Chemotherapeutics
17.7.3.3. Rest of Latin America Compounding Chemotherapy Market Revenue
(US$ Mn) and Forecasts, By Type
17.7.3.3.1. Gravimetric
17.7.3.3.2. Volumetric
17.7.3.4. Rest of Latin America Compounding Chemotherapy Market Revenue
(US$ Mn) and Forecasts, By Technology
17.7.3.4.1. With Robotic Arms
17.7.3.4.2. Without Robotic Arms
17.7.3.5. Rest of Latin America Compounding Chemotherapy Market Revenue
(US$ Mn) and Forecasts, By End-Users
17.7.3.5.1. Hospitals and Clinics
17.7.3.5.2. Cancer Treatment Centers
17.7.3.5.3. Others
17.8. Key
Segment for Channeling Investments
17.8.1. By
Country
17.8.2. By
Offering
17.8.3. By
Dosage
17.8.4. By Type
17.8.5. By
Technology
17.8.6. By
End-Users
18. Competitive Benchmarking
18.1. Market
Share Analysis, 2019
18.2. Global
Presence and Growth Strategies
18.2.1. Mergers
and Acquisitions
18.2.2. Product
Launches
18.2.3. Investments
Trends
18.2.4. R&D
Initiatives
19. Player Profiles
19.1. ARxIUM
19.1.1. Company
Details
19.1.2. Company
Overview
19.1.3. Product
Offerings
19.1.4. Key
Developments
19.1.5. Financial
Analysis
19.1.6. SWOT
Analysis
19.1.7. Business
Strategies
19.2. B. Braun Melsungen AG
19.2.1. Company
Details
19.2.2. Company
Overview
19.2.3. Product
Offerings
19.2.4. Key
Developments
19.2.5. Financial
Analysis
19.2.6. SWOT Analysis
19.2.7. Business
Strategies
19.3. Baker
19.3.1. Company
Details
19.3.2. Company
Overview
19.3.3. Product
Offerings
19.3.4. Key
Developments
19.3.5. Financial
Analysis
19.3.6. SWOT
Analysis
19.3.7. Business
Strategies
19.4. Baxter
19.4.1. Company
Details
19.4.2. Company
Overview
19.4.3. Product
Offerings
19.4.4. Key
Developments
19.4.5. Financial
Analysis
19.4.6. SWOT
Analysis
19.4.7. Business
Strategies
19.5. COMECER
S.p.A
19.5.1. Company
Details
19.5.2. Company
Overview
19.5.3. Product
Offerings
19.5.4. Key
Developments
19.5.5. Financial
Analysis
19.5.6. SWOT
Analysis
19.5.7. Business
Strategies
19.6. Dedalus
Italia S.p.A.
19.6.1. Company
Details
19.6.2. Company
Overview
19.6.3. Product
Offerings
19.6.4. Key Developments
19.6.5. Financial
Analysis
19.6.6. SWOT
Analysis
19.6.7. Business
Strategies
19.7. Equashield
LLC.
19.7.1. Company
Details
19.7.2. Company
Overview
19.7.3. Product
Offerings
19.7.4. Key
Developments
19.7.5. Financial
Analysis
19.7.6. SWOT
Analysis
19.7.7. Business
Strategies
19.8. Grifols
International, S.A
19.8.1. Company
Details
19.8.2. Company
Overview
19.8.3. Product
Offerings
19.8.4. Key
Developments
19.8.5. Financial
Analysis
19.8.6. SWOT
Analysis
19.8.7. Business
Strategies
19.9. Icon
Group
19.9.1. Company
Details
19.9.2. Company
Overview
19.9.3. Product
Offerings
19.9.4. Key
Developments
19.9.5. Financial
Analysis
19.9.6. SWOT
Analysis
19.9.7. Business
Strategies
19.10. ICU
Medical
19.10.1. Company
Details
19.10.2. Company
Overview
19.10.3. Product
Offerings
19.10.4. Key
Developments
19.10.5. Financial
Analysis
19.10.6. SWOT
Analysis
19.10.7. Business
Strategies
19.11. Omnicell
19.11.1. Company
Details
19.11.2. Company
Overview
19.11.3. Product
Offerings
19.11.4. Key
Developments
19.11.5. Financial
Analysis
19.11.6. SWOT
Analysis
19.11.7. Business
Strategies
19.12. Other Market
Participants
20. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User
and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.